Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.

McNeil C.

J Natl Cancer Inst. 2013 Jul 3;105(13):922-3. doi: 10.1093/jnci/djt179. Epub 2013 Jun 18. No abstract available.

PMID:
23781000
2.

Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.

Jacobson P, Uberti J, Davis W, Ratanatharathorn V.

Bone Marrow Transplant. 1998 Aug;22(3):217-25. Review.

3.

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.

Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R.

Bone Marrow Transplant. 1999 Oct;24(7):763-8.

4.

Tacrolimus in hematopoietic stem cell transplantation.

Fortune K, Couriel D.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):835-41. doi: 10.1517/17425250903044959. Review.

PMID:
19545215
5.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

6.

Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.

Schwinghammer TL, Bloom EJ.

Clin Pharm. 1993 Oct;12(10):736-61. Review.

PMID:
8258255
7.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2004 May;10(5):328-36.

8.

Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.

Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A.

Bone Marrow Transplant. 2005 Jun;35(11):1095-9.

PMID:
15821773
9.
10.
13.

Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.

Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T, Muramatsu H, Morishima Y, Kodera Y.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1603-8. doi: 10.1016/j.bbmt.2009.08.012. Epub 2009 Oct 4.

14.

Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.

Yoshihara T, Okada K, Kobayashi M, Kikuta A, Kato K, Adachi N, Kikuchi A, Ishida H, Hirota Y, Kuroda H, Nagatoshi Y, Inukai T, Koike K, Kigasawa H, Yagasaki H, Tokuda K, Kishimoto T, Nakano T, Fujita N, Goto H, Nakazawa Y, Kanegane H, Matsuzaki A, Osugi Y, Hasegawa D, Uoshima N, Nakamura K, Tsuchida M, Tanaka R, Watanabe A, Yabe H.

Int J Hematol. 2007 Apr;85(3):246-55.

PMID:
17483063
15.

Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.

Meisel R, Laws HJ, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Schmitz M, Fischer J, Göbel U, Enczmann J, Dilloo D.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1338-45. Epub 2007 Sep 21.

16.

Impact of CD34 cell dose on acute graft versus host disease after allogeneic bone marrow stem cell transplantation.

Damiani D, Sperotto A, Geromin A, Stocchi R, Fanin R.

Leuk Lymphoma. 2002 Nov;43(11):2245-7. No abstract available.

PMID:
12533058
17.

Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT.

Honda A, Kakihana K, Aoki J, Kobayashi T, Doki N, Sakamaki H, Ohashi K.

Bone Marrow Transplant. 2013 Feb;48(2):307-9. doi: 10.1038/bmt.2012.128. Epub 2012 Jul 2. No abstract available.

PMID:
22751000
18.

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.

Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS.

Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22. doi: 10.1016/j.bbmt.2010.09.017. Epub 2010 Dec 4.

19.

Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.

Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, Hadjibabaie M, Namdar R, Nedaeifard L, Ghaffari H, Alimoghaddam K.

Biol Blood Marrow Transplant. 2008 Mar;14(3):301-8. doi: 10.1016/j.bbmt.2007.12.491.

20.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.

Blood. 2000 Sep 15;96(6):2062-8.

Supplemental Content

Support Center